Literature DB >> 6957686

[Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application].

H J Langermann, G Henze, M Wulf, H Riehm.   

Abstract

A retrospective statistical analysis of the acute lymphoblastic leukemia study BFM 70/76 revealed the prognosis being strongly dependent on the initial leukemia cell count/mm3 in the peripheral blood, and the enlargement of liver and spleen below the costal margin. Based on postmortem examinations reported in the literature a method was developed to estimate the tumor mass in these three compartments in an order of magnitude. The estimated blast cell mass related to the patient's body weight proved to be highly significant (p much less than 0.001). Simplification of the method led to the definition of a "risk factor" allowing the separation of patients into 3 groups with a distinctly different risk for relapse. In the current study BFM 81 the risk factor is used to stratify patients with respect to the individually needed therapeutic intensity.

Entities:  

Mesh:

Year:  1982        PMID: 6957686     DOI: 10.1055/s-2008-1033807

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  3 in total

1.  No adverse prognostic influence of hepatitis B virus infection in acute childhood lymphoblastic leukemia.

Authors:  F Lampert; W R Willems; U Bertram; F Berthold
Journal:  Blut       Date:  1987-08

2.  Prolonged intrathecal chemotherapy replacing cranial irradiation in high-risk acute lymphatic leukaemia: long-term follow up with cerebral computed tomography scans and endocrinological studies.

Authors:  H Hasle; J Helgestad; J K Christensen; B B Jacobsen; J Kamper
Journal:  Eur J Pediatr       Date:  1995-01       Impact factor: 3.183

3.  Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia.

Authors:  M Schrappe; A Reiter; H Riehm
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.